Hot Blue Chip Stocks To Buy For 2018

tags:VCSH,EBSB,SRPT,RMP,

Shutterstock

A few weeks ago we discussed how you can make 12% annually, forever, from stocks. Now let’s apply those lessons to 2017, and highlight five that should do even better (17%+ returns) this year (and likely beyond).

Remember, projecting our returns from any given stock is simple. We simply add together the three ways it can pay us:

Its current dividend.

A future dividend hike.

Share repurchases.

It also helps if the stock is inexpensive, as buybacks deliver more bang for management’s buck. So let’s stick with stocks that are dirt-cheap, trading for 10-times free cash flow (FCF) or less for this exercise.

Here’s an example of a stock ready to return 17% or more over the next year. Blue chip refiner Valero (VLO) has a great management team that knows how to make money no matter what happens with energy prices.

Hot Blue Chip Stocks To Buy For 2018: Vanguard Short-Term Corporate Bond ETF(VCSH)

Advisors' Opinion:

• [By Luke Kawa]

  The three-month moving average of weekly flows into the iShares Short Maturity Bond exchange-traded fund (NEAR), Floating Rate Bond ETF (FLOT), SPDR Bloomberg Barclays Short Term High-Yield Bond ETF (SJNK), PowerShares Senior Loan Portfolio (BKLN) and Vanguard Short-Term Corporate Bond ETF (VCSH) sank to a record low outflow of $18 million after the first week of 2018.

Hot Blue Chip Stocks To Buy For 2018: Meridian Interstate Bancorp Inc.(EBSB)

Advisors' Opinion:

• [By Logan Wallace]

  BidaskClub upgraded shares of Meridian Bancorp (NASDAQ:EBSB) from a hold rating to a buy rating in a research report sent to investors on Friday morning.

Hot Blue Chip Stocks To Buy For 2018: Sarepta Therapeutics, Inc.(SRPT)

Advisors' Opinion:

• [By Keith Speights]

  But some stocks don't take nearly that long to double. Three stocks in particular�have doubled investors' money -- and more -- in just the last 12 months. Here's why Nektar Therapeutics (NASDAQ:NKTR), CRISPR Therapeutics (NASDAQ:CRSP), and Sarepta Therapeutics (NASDAQ:SRPT) became such huge winners -- and whether or not their impressive momentum can continue.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Sarepta Therapeutics (NASDAQ:SRPT) had its target price increased by Morgan Stanley from $87.00 to $91.00 in a report issued on Friday. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.

Hot Blue Chip Stocks To Buy For 2018: Rice Midstream Partners LP(RMP)

Advisors' Opinion:

• [By Logan Wallace]

  Williams Companies (NYSE: WMB) and Rice Midstream Partners (NYSE:RMP) are both oils/energy companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

• [By Stephan Byrd]

  These are some of the media headlines that may have effected Accern’s scoring:

  Get Rice Midstream Partners alerts: Investor Expectations to Drive Momentum within Balchem, Beacon Roofing Supply, Rice Midstream Partners LP, LTC Properties, Ubiquiti Networks, and 1st Source �� Discovering Underlying Factors of Influence (finance.yahoo.com) Rice Midstream Partners (RMP) Rating Lowered to Strong Sell at ValuEngine (americanbankingnews.com) Zacks: Brokerages Expect Rice Midstream Partners (RMP) to Announce $0.40 EPS (americanbankingnews.com) Rice Midstream: 1Q Earnings Snapshot (finance.yahoo.com) Rice Midstream Partners (RMP) Announces $0.30 Dividend (americanbankingnews.com)

  RMP stock opened at $17.88 on Friday. The stock has a market capitalization of $1,871.10, a P/E ratio of 10.63, a P/E/G ratio of 0.74 and a beta of 1.17. Rice Midstream Partners has a 52 week low of $16.87 and a 52 week high of $26.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.91 and a quick ratio of 2.91.